期刊文献+

重组HIV-1腺病毒伴随病毒的构建及表达 被引量:2

Construction and expression of recombinant adeno associated HIV 1 virus
原文传递
导出
摘要 目的 构建带有HIV 1gag或 gp12 0基因的重组腺病毒伴随病毒AAV HIV gag或AAV HIVgp12 0。方法 共转染法获取重组AAV HIV ;免疫酶法检测病毒滴度。结果 测定制备的重组腺病毒伴随病毒AAVgag42 ,AAVgp42 ,AAVgpRj6 ,病毒滴度在 10 4~ 10 5 范围。结论 构建了带有 gag和gp12 0基因的重组AAV HIV ,可以感染真核细胞并有较高的表达 ,可以用于做靶细胞 ,为发展新型的HIV Objective Plasmid of AAV vector with HIV 1 gag and gp 120 were constructed respectively. Methods The recombinant AAV HIV gag and gp120 viruses were obtained by co transfection of AAV HIV plasmid and Adenovirus 5 in 293 cells. Results The recombinant AAV HIV virus expressed well and the titer of the recombinant viruses were between 10 4 10 5. Conclusion The recombinant AAV HIV virus can be used to infect the target cells for detection of cellular immunity and for vaccine studies.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 2000年第4期322-324,共3页 Chinese Journal of Experimental and Clinical Virology
关键词 HIV-1 T淋巴细胞 细胞毒性 依赖病毒属 HIV-1 T lymphocytes,cytotoxic Adeno associated viruses
  • 相关文献

参考文献4

二级参考文献5

  • 1邵一鸣,病毒学报,1996年,12卷,9页
  • 2邵一鸣,Tenth International Conference on AIDS,380A,1994年
  • 3邵一鸣,病毒学报,1994年,4卷,291页
  • 4邵一鸣,中华流行病学杂志,1991年,12卷,129页
  • 5陈钧,管永军,邵一鸣,田春桥,赵全壁,张桂云,张家鹏,段松,JosefKostler,HansWolf.云南省陇川县HIV-1流行毒株膜蛋白基因C2-V3区序列测定和分析[J].中华微生物学和免疫学杂志,1997,17(1):1-6. 被引量:6

共引文献4

同被引文献34

  • 1刘雁征,周玲,王琦,叶树清,李红霞,曾毅.HIV DNA疫苗与重组腺病毒伴随病毒联合免疫效果的研究[J].中华实验和临床病毒学杂志,2004,18(3):251-254. 被引量:1
  • 2DANA FARBER Cancer Institute. The report of Dana Farber Cancer Institute[J]. Biotechnology News, 1999, 19(4 ): 5.
  • 3ASAKURA Y, LIU L, SHONO N, et al. Thl-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production [J]. Clin Exp Immunol, 2000, 119 (1):130-139.
  • 4TANGHE A, CEFEVRE P, DENIS O, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors[J]. J Immunol, 1999, 162(2):1113-1119.
  • 5First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host respanse[J]. Infect Dis, 1998, 178(1): 92-100.
  • 6MACGREGOR RR, BOYER JD, UGEN KE, et al. first human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response[J]. Infect Dis, 1998, 178(1): 92-100.
  • 7MUTHUMANI K. et al. V accine, 2002, 20 (15): 199922003.
  • 8MUTHUMANI K, BAGARAZZI M, CONWAY D, et al. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts,and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques [J]. Vaccine, 2003, 21 (7-8):629-637.
  • 9BAROUCH DH, PAU MG, CUSTERS JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J]. Immunol, 2004, 172:6290-6297.
  • 10LETVIN NL, HUANGY, CHAKRABARTI BK, et al. 2004.eterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys[J]. Virol, 2004, 78: 7490-7497.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部